IK Partners’ Post

As the #UNGA meets to discuss anti-microbial resistance, Tenmile has made an investment in Lumos Diagnostics, furthering our commitment to support commercial efforts to stem the threat of #AMR. How does Lumos play a role in this fight? About a month ago, there was a case of whooping cough (caused by Bordetella pertussis, a bacterial infection) in my daughter's pre-school. A week later my daughter started coughing and we promptly visited our GP. While the GP felt it was unlikely to be bacterial, the definitive test would take 2-3 days and so to be safe, recommended #antibiotics. As a parent, it's hard not to take this advice and promptly started antibiotic treatment. Three days later we got the news that it was not a bacterial infection. There was no need for antibiotics, yet we've already exposed our daughters microbiome out of caution, becoming a part of a scary statistic. Approximately 30% of antibiotics are prescribed when they aren't necessary. This is where FebriDx steps in. Lumos has developed FebriDx as a point-of-care diagnostic to distinguish bacterial from non-bacterial infections. In 10 minutes, a GP could have identified that my daughter's cough was not caused by a bacterial infection and that antibiotics would not help. Along with novel antibiotics (Revagenix, Inc.) and vaccines (LimmaTech Biologics AG), #diagnostics will play a key role in identifying bacterial infections, avoiding over-prescription and reducing the burden of AMR.

💰 Moximed secures $91m financing to commercialise its MISHA knee system The new investors, including Cormorant Asset Management and Warren Point Capital, have participated in the financing round, along with existing investors. The existing investors include New Enterprise Associates (NEA), Future Fund, Advent Life Sciences, Gilde Healthcare, Vertex Ventures HC, GBS Venture Partners, and Morgenthaler Ventures. Moximed intends to use the proceeds from the financing round to advance the commercialisation of its MISHA Knee System in the US. Read more online: https://lnkd.in/efXVBGq2 📰 Follow Medical Device Developments to receive the latest medical device news daily and to subscribe to our weekly newsletter #MedicalDeviceDevelopments #medicaldevices #medicalmanufacturing

Pulsed Field Ablation Innovator, Arga, has just raised €54 million in an oversubscribed financing round. The investors included Advent Life Sciences (UK), Earlybird Health (Germany), a new investor Gilde Healthcare (the Netherlands) as well as an undisclosed strategic investor. This start-up was founded by David Naele and Randy Werneth in 2020, to develop Coherent Sine-Burst Electroporation™ (CSE™), a next-generation cardiac ablation system for treating cardiac arrhythmias, including atrial fibrillation. Supporting Argá Medtech SA since its formation, Kellerhals Carrard advised on the Swiss contractual aspects of this round and collaborated with Wilson Sonsini Goodrich & Rosati from the US side. The Kellerhals Carrard team was led by Jean-Luc Chenaux (pictured) (Partner, M&A), and further comprised Frédéric Rochat (Partner, M&A), François Kaiser (Partner, M&A), Serge Migy (Partner, Tax) Virginie A. Rodieux (Partner, IP) as well as Cindy Liu-Ung and Joséphine Marmy (Senior Associates, M&A) and Brian Jurt (Tax advisor). Read the article >> https://lnkd.in/dJe2u5Qu #Legalcommunitych #legaladvisor #financinground

Thrilled by Eurazeo’s H1 successes we had the pleasure to present with William Kadouch-Chassaing.   Our H1 results reflected the successful execution of our strategic plan in line with our medium-term objectives presented to the market in November 2023. We reported a dynamic growth in asset management with a strong momentum in fundraising up +63% with €2.1bn raised in H1 2024, including €453M from private clients. We also increased realizations, including Amolyt Pharma (Biotech), Onfido (Venture), LumApps (Growth), EFESO Management Consultants, DORC Dutch Ophthalmic Research Center (International), Peters Surgical, and I-TRACING.   We warmly thank our more than 400 great talents, as well as our clients, investors, entrepreneurs and shareholders for their trust and support in the implementation of our strategic roadmap.   🔎 Read more: https://lnkd.in/eY89RySe   #PrivateEquity #AssetManagement #MidMarket #Growth #Impact #strategy #PowerBetterGrowth #results #finance

For this first trading updates of 2024, Eurazeo continues to grow its asset management activity and increases realizations. Eurazeo is focused on delivering its strategic and operational roadmap and confirms its positive outlook for 2024 with a rich and diversified fundraising pipeline. Since the beginning of the year, the Group has announced several exits across a wide range of its asset classes, all realized in good terms : Amolyt Pharma, Onfido, DORC Dutch Ophthalmic Research Center (International) and Peters Surgical. Eurazeo benefits from substantial leeway for its future investments.   📰 Read more: https://lnkd.in/e-8s5wUR   #PowerBetterGrowth #PrivateEquity #MidMarket #growth #impact #privatemarkets #economy #digitalisation #transition #ESG #fundraising

US-based global investment giant KKR has signed the definitive agreements for acquiring Healthium Medtech Ltd, a leading Indian medical devices company, from an affiliate of funds advised by Apax Partners LLP, a leading global private equity advisory firm. While the firm didn't disclose the financial terms of the deal, an ET report said KKR has valued the Indian company at Rs 7,000 crore, inclusive of debt. Healthium Medtech develops, manufactures and sells surgical products globally. Apax Funds acquired Healthium in 2018. Read the full story here: 👇 https://lnkd.in/d5BPA-mC #investment #healthcare #acquisition #Investors #company #indianstartupnews

Braveheart Investment Group PLC (AIM:BRH) has confirmed it has written down the values of its two main holdings - instrument company Paraytec and Kirkstall, which has developed technology to replace animals in medical testing. "The board believes that, with time, both Kirkstall and Paraytec could have the potential to increase in value and provide exit opportunities for the company, but it is prudent to write the values down to zero at the current time," the company said in commentary accompanying its prelims. As a result of these adjustments, the company posted a pre-tax loss for the 12 months ending March 31 of £8.19 million. It exited the year with £1.74 million of cash and owns investments worth £1.65 million. Investors were told Braveheart had implemented a "range of actions to rationalise the company's cost base and to conserve cash".     More at #Proactive #ProactiveInvestors http://ow.ly/1n4r105xCgm

Massachusetts PE news in February 📣 📍 Charlesbank Capital Partners takes over as the lead investor in Perspective Financial Group, succeeding CBPE Capital, signaling a strategic shift in ownership. 📍 Berkshire Partners-backed AHEAD acquires CDI, solidifying its position as a dominant force in the global digital platforms market with a combined entity valued at $3.7 billion. 📍 Sanofi Ventures backed Sudo Biosciences secures $147 million in Series B financing from notable investors like Dementia Discovery Fund, Leaps by Bayer, and UPMC Enterprises, highlighting significant interest in its precision TYK2 inhibitors. 📍 Nordic Capital's acquisition of a majority stake in ActiveViam underscores the growing demand for data analytics in financial risk management, particularly amidst regulatory changes and the rise of big data. As part of the transaction, Guidepost Growth Equity, which first invested in ActiveViam in 2019, will sell all of its shares. 📍 Totango and Catalyst's merger, supported by Great Hill Partners, creates a robust customer growth platform, integrating enterprise customer success software with advanced analytics and AI capabilities to drive revenue growth from existing customers, reflecting a strategic response to evolving market demands #privateequity #massachusetts #mergersandacquisitions

I guess the team Pacific Equity Partners are big fans of Dr Nick from the Simpsons or maybe it’s just defensible assets? In any event it would appear that they are having a good look at Integral Diagnostics (IDX) as part of their second Secure Assets Fund. Integral Diagnostics (IDX) has struggled recently with a market cap of $490m on $89m of EBITDA. Radiology clinics have been somewhat of a darling for private equity presenting defensible assets with high barriers of entry and stable cashflows. It would appear that Pacific Equity Partners team led by Andrew Charlier, Paul Foster and Evan Hattersley are keen to get their teeth stuck into the sector with a possible takeover offer for underperforming Integral Diagnostics (IDX) being a logical entry point. Pacific Equity Partners are arguable the leading private equity firm for public to private transactions having completed a number of them with great success including the most recent of Healthia Limited Australia. I would expect that a deal will be done quickly if the target ticks the boxes for the team at PEP. Certainly plenty of action at the moment in listed and unlisted markets! #privateequity #takeover #mergersandacquisitions #corporateadvisory

Only put off until tomorrow what you are willing to die having left undone. **Altos Venture Boosts Stake in Onconetix to 5%: A Promising Opportunity for HSA Investors** 🚀💼💰 Altos Venture, a renowned VC firm, has made a bold move by significantly increasing its stake in Onconetix, the top gainer in the US market. Back in December 2023, Altos Venture had already disclosed a 5% stake in this transformative healthcare company. Now, their recent boost demonstrates their confidence in Onconetix's potential for immense growth and success. This exciting development presents an incredible opportunity for HSA investors looking to make the most of their accounts. Onconetix's innovative solutions and breakthrough technologies in the healthcare sector make them a prime investment choice. By leveraging the power of your Health Savings Account, you can actively participate in the expansion of this visionary company and reap significant financial rewards. Act now to avoid the Fear of Missing Out! Don't let this golden chance slip away. Take advantage of Altos Venture's increased stake in Onconetix to enhance your HSA portfolio and secure a prosperous future for yourself and your loved ones. Invest wisely, stay ahead of the curve, and grow your wealth while contributing to the advancement of healthcare technology. #HSA #Investing #Healthcare #Health #Family #Wellness 💪💸📈✨🏥 Summary: Altos Venture has raised its stake in Onconetix to 5%, reflecting their unwavering belief in the company's potential. This presents an exciting opportunity for HSA investors to capitalize on the growth and advancements in the healthcare industry. By taking action now, investors can ensure they don't miss out on the chance to grow their funds while contributing to the transformation of healthcare technology. #FearOfMissingOut #Opportunity #InvestWise